Efficacy and safety of a monoclonal antibody recognizing lnterleukin-8 in COPD: A pilot study

Chest

Volumn 126, Issue 3, 2004, Pages 926-934

  Mahler, Donald A ^a,c   Huang, Saling ^b   Tabrizi, Mohammad ^b   Bell, Gregory M ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Abgenix Inc   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chemokine; Interleukin 8; St. George Respiratory Questionnaire; Transition dyspnea index

Indexed keywords

BUFFER; CHEMOKINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 8; SALBUTAMOL;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATION; LEG EDEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TIME; UNITED STATES; WALKING;

EID: 4544275759     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3.926     Document Type: Article

References (40)

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
2. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160:893-898
3. Keatings VM, Collins PD, Scott DM, et al. Differences in interleuldn-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153:530-534
4. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155:449-453
5. Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12:380-386
6. Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15:109-115
7. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989; 140:1527-1537
8. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-280
9. Patel IS, Roberts NJ, Lloyd-Owen SJ, et al. Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 2003; 22:94-99
10. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
11. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358:265-270
12. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091
13. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease: Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941-1947
14. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81
15. Yang XD, Corvalan JR, Wang P, et al. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66:401-410
16. 4. Chest 2003; 123:1240-1247
17. Nadel JA. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000; 117:386S-389S
18. Fabri LM, Hurd SS, for the GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22:1-2
19. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959; 1:257-266
20. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758
21. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19:936-943
22. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1628-1630
23. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209-216
24. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224
25. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404
26. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmetol (50 μg) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843
27. O'Donnell DE, McGuire MA, Samis L, et al. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995; 152:2005-2013
28. Readon J, Awad E, Normandin E, et al. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994; 105:1046-1052
29. Ries AL, Kaplan RM, Myers R, et al. Maintenance after pulmonary rehabilitation in chronic lung disease. Am J Respir Crit Care Med 2003; 167:880-888
30. Harver A, Mahler DA, Daubenspeck JA. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989; 111:117-124
31. Lisboa C, Munoz V, Beroiza T, et al. Inspiratory muscle training in chronic airflow limitation: comparison of two different training loads with a threshold device. Eur Respir J 1994; 7:1266-1274
32. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327
33. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117:398S-401S
34. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248-255
35. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21:267-272
36. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody: rhuMAb-E25 Study Group. N Engl J Med 1999; 341:1966-1973
37. Rennard S, Decramer M, Calverley PMA, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20:799-805
38. Van den Boom G, Rutten-van Molken MPMH, Molema J, et al. The cost effectiveness of early treatment with fluticasone propionate 250 μg twice a day in subjects with obstructive airway disease. Am J Respir Crit Care Med 2001; 164:2057-2066
39. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2002; 167:1655-1659
40. De Boer WI. Cytokines and therapy in COPD: a promising combination? Chest 2002; 121:209S-218S